Pure Global AI
NCT06380361Recruiting

InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology

SensomeClinicalTrials.govdeviceDevice trial
Verified
Study focus
Disease/Condition
Lung Cancer
Drug/Device/Intervention
BioSpy System
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Sensome
Location
Brisbane, Australia
Timeline & enrollment
Phase
N/A
Start date
Apr 02, 2024
End date
Apr 01, 2025
Enrollment
30 participants
Primary outcome

The ability of BioSpy System to acquire electrophysiological measurements in the relevant tissues during bronchoscopic biopsy.

Summary

The objective of the study is to evaluate the feasibility of the BioSpy System sensor to
 differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial
 tumors and peripheral lung nodules and masses.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm of bronchus and lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm: Overlapping lesion of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06380361
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06380361 through Pure Global AI's free database. This phase not specified trial is sponsored by Sensome and is currently Recruiting. The study focuses on Lung Cancer. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.